The pharmacometrics group led by France Mentre (IAME, INSERM, Univ Paris) is very pleased to host a FREE ISoP Statistics and Pharmacometrics (SxP) SIG local event at Faculté Bichat, 16 rue Henri Huchard, 75018 Paris, France, on Thursday afternoon the 11th of July 2019. It will features talks from Professor Andrew Gelman, Univ of Columbia…
We are delighted to invite you to the first International Society of Pharmacometrics (ISoP) Regional Quantitative Systems Pharmacology (QSP) Day 2019, co-hosted by the ISoP QSP Special Interest Group (ISoP QSP SIG) and Bristol-Myers Squibb (BMS). The event is intended to highlight some of the recent achievements in QSP, illustrate application areas, and promote networking,…
Registration for ACoP10 (October 20 – 23, 2019) as well as the ACoP10 Pre-conference (October 20, 2019) is open! Early-bird registration will be June 1, 2019 to July 31, 2019. If you have not already done so, renew your ISoP membership for 2019 before you register for ACoP10 to receive the discounted member rate. Attendees that have…
Our new website has gone live, after many months of development. We hope you like it! Let us know if you find anything that needs adding, fixing or improving, or if you have any other comments. Member functions are currently being overhauled, but should be available within the next few days.
2019 is going to be a pivotal year for ISoP. We have a number of significant changes coming down the road, the result of a lot of time and planning by our Board and our teams of volunteers. ISoP is growing from the equivalent of a plucky startup into a mature scientific society: by 2023…
Quantitative clinical pharmacology is well established in most parts of the world, but the low- and middle-income countries (LMIC’s) are underrepresented. To address this need, a team of pharmacologists have started a new organization known as Pharmacometrics Africa. I asked some of them to tell us more about their vision for the future: View full…
Choosing optimal doses to be used in clinical trials for potential new therapies is difficult as data can be limited. The ability to identify relevant doses is further complicated when the difference between concentrations that are efficacious and those causing toxicity are narrow. Add to these issues the need to not overshoot or undershoot a…